Completed

Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

ceftazidime and amikacin

Drug
Who is being recruted

Healthcare-Associated Pneumonia+13

+ Bacterial Infections and Mycoses

+ Bacterial Infections

Over 18 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: October 2004
See protocol details

Summary

Principal SponsorGroupe Hospitalier Pitie-Salpetriere
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2004

Actual date on which the first participant was enrolled.

Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.

Official TitleAssessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa
NCT00786305
Principal SponsorGroupe Hospitalier Pitie-Salpetriere
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Healthcare-Associated PneumoniaBacterial Infections and MycosesBacterial InfectionsCross InfectionIatrogenic DiseaseInfectionsLung DiseasesPathologic ProcessesPneumoniaPseudomonas InfectionsRespiratory Tract DiseasesRespiratory Tract InfectionsPathological Conditions, Signs and SymptomsGram-Negative Bacterial InfectionsDisease AttributesPneumonia, Ventilator-Associated

Criteria

2 inclusion criteria required to participate
Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa
Written informed consent provided by the relatives
4 exclusion criteria prevent from participating
Pseudomonas aeruginosa resistant to ceftazidime and amikacin
Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment
Severe septic shock and severe hypoxemia
Allergy to ceftazidime or amikacin

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental

Group II

Active Comparator

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital

Paris, FranceOpen Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital in Google Maps
CompletedOne Study Center